鲍勃 · 阿特威尔

Bob Atwill is a Principal of Eaton Square and has over 30-years experience in the global pharmaceutical, biotechnology, cellular therapies, COVID-19, CAR-T IO, IT, medical device, diagnostic, healthcare services, life science and consultancy sectors. He has been a CEO for over 17 years and a Senior Executive and Corporate Officer in NYSE, LSE & ASX organisations since 1997.

 

He is currently Head of Asia-Pacific Region for Humanigen, Inc. the NASDAQ-listed clinical stage biopharmaceutical company, developing an immunology and immuno-oncology portfolio of monoclonal antibodies for COVID-19, CAR-T therapy and acute GvHD.

Bob has grown two Strategy and Business Development consultancies and led a diverse range of M&A, Capital Raising and Corporate activities. He has also been SVP New Business & Collaborations for Benitec Biopharma the NASDAQ/ASX-listed gene therapy company, CEO of Cytomatrix (now Nohla Therapeutics based in Seattle), Managing Director of Fitgenes Australia Ltd and was a Group Executive and Regenerative Medicine Division CEO for Allied Healthcare Group (now Admedus).

 

鲍勃曾借助Mesenchymal Precursor Cells投资组合,就战略和商业化事宜向澳交所上市公司(Mesoblast)提供咨询建议;他也正在Cyto Therapeutics公司(圣地亚哥国际干细胞公司在澳大利亚的子公司)担任总监。同时,他也曾是Clinical Cell Culture (现已更名为Avita Medical),一家在澳大利亚证交所上市的干细胞治疗及器械公司的首席执行官和执行总裁。最后,他还曾是Corin 集团公司的销售总裁,以及Sun Healthcare集团公司欧洲地区的执行总裁。

鲍勃拥有着布里斯托大学的生物化学学士(荣誉)学位和阿什里奇管理学院的MBA学位。同时,他也参加了耶鲁大学和加州大学洛杉矶分校的行政/总裁计划。最后,鲍勃还是董事学会和英国皇家特许行销学会的成员。